Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report

9 views | Jul 13 2021

Zhiying Lin et al. found that the use of BRAF inhibitors combined with inhibitors of these seven genes may be a useful remedial treatment option. [Read the Full Post]

YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation

6 views | Jun 15 2021

Kyungjoo Cho et al. indicated that drug delivery into liver cancer was impaired by YAP/TAZ signaling in tumor cells and subsequent activation of stroma by the signaling. [Read the Full Post]

83JAK-STAT inhibition mediates romidepsin and mechlorethamine synergism in Cutaneous T-cell Lymphoma

9 views | Jun 07 2021

Jose R Cortes et al. found a role for romidepsin plus mechlorethamine in combination in the treatment of CTCL and uncovered a previously unrecognized role for JAK-STAT signaling in the response to romidepsin and romidepsin-based combination therapies in SS. [Read the Full Post]

Hypoxia induces chemoresistance of esophageal cancer cells to cisplatin through regulating the lncRNA-EMS/miR-758-3p/WTAP axis

10 views | Jun 04 2021

Zi-Jiang Zhu et al. uncovered a critical lncRNA-EMS/miR-758-3p/WTAP axis in regulating hypoxia-mediated drug resistance to cisplatin in EC. [Read the Full Post]

ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations

10 views | May 24 2021

Silvia Angela Debonis et al. thought that although there was no standard of care for the treatment of IMT, identifying genomic alterations could help to redefine the management of patients with negative-ALK disease. [Read the Full Post]

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status

18 views | Apr 29 2021

Rui Ma et al. found that the BRAF inhibitor AZ304 had broad spectrum antitumour activity, which was significantly enhanced by combination with Cetuximab in colorectal cancers in vitro and in vivo. [Read the Full Post]

Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer

13 views | Apr 28 2021

Fatemeh Khojasteh Poor et al. summarized the FDA-approved prescription drugs that targeted the MAPK signaling pathway in women with BC. [Read the Full Post]

Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells

14 views | Apr 28 2021

Siyeon Park et al. found that human NRAS-mutant NSCLC cells were moderately sensitive to pan-RAF inhibitors. [Read the Full Post]

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

20 views | Apr 01 2021

Kelli-Ann Monaco et al. found that LXH254 was a novel RAF inhibitor, which was able to inhibit dimerized BRAF and CRAF, as well as monomeric BRAF, while largely sparing ARAF. [Read the Full Post]

Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor

19 views | Mar 16 2021

Jing-Quan Wang et al. indicated that AZ-628 could be used in combination chemotherapy against ABCG2-mediated MDR in cancers. [Read the Full Post]